Traders overwhelmingly price the flu hospitalization rate at 80–90 per 100,000 population for Week 10, 2026—aligning with CDC FluView cumulative rates observed during peak influenza season weeks in recent years, such as 82 in 2023–24 and 88 in 2022–23. This consensus reflects epidemiological patterns where H3N2-dominant seasons typically accumulate 80–90 hospitalizations per 100k by early March, driven by school reopenings, waning vaccine efficacy, and baseline transmission dynamics. Supporting evidence includes consistent historical baselines amid stable vaccination coverage around 45%. Challenges could arise from an unusually mild season like 2024–25's low activity persisting due to hybrid immunity, or a surge exceeding 100 from novel strains or low uptake, though models imply low probability.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日Flu Hospitalization Rate Week 10, 2026?
Flu Hospitalization Rate Week 10, 2026?
80–90 100.0%
<60 <1%
60–70 <1%
70–80 <1%
$0.00 Vol.
$0.00 Vol.
Mar 20, 2026
<60
No
60–70
No
70–80
No
80–90
Yes
90–100
No
100+
No
80–90 100.0%
<60 <1%
60–70 <1%
70–80 <1%
$0.00 Vol.
$0.00 Vol.
Mar 20, 2026
<60
$0 Vol.
No
60–70
$0 Vol.
No
70–80
$0 Vol.
No
80–90
$0 Vol.
Yes
90–100
$0 Vol.
No
100+
$0 Vol.
No
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.Traders overwhelmingly price the flu hospitalization rate at 80–90 per 100,000 population for Week 10, 2026—aligning with CDC FluView cumulative rates observed during peak influenza season weeks in recent years, such as 82 in 2023–24 and 88 in 2022–23. This consensus reflects epidemiological patterns where H3N2-dominant seasons typically accumulate 80–90 hospitalizations per 100k by early March, driven by school reopenings, waning vaccine efficacy, and baseline transmission dynamics. Supporting evidence includes consistent historical baselines amid stable vaccination coverage around 45%. Challenges could arise from an unusually mild season like 2024–25's low activity persisting due to hybrid immunity, or a surge exceeding 100 from novel strains or low uptake, though models imply low probability.
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
マーケット開始日： Mar 12, 2026, 4:38 PM ET
音量
$0終了日
Mar 20, 2026マーケット開始日
Mar 12, 2026, 4:38 PM ETResolver
0x69c47De9D...提案された結果: No
異議申し立てなし
最終結果: No
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.Traders overwhelmingly price the flu hospitalization rate at 80–90 per 100,000 population for Week 10, 2026—aligning with CDC FluView cumulative rates observed during peak influenza season weeks in recent years, such as 82 in 2023–24 and 88 in 2022–23. This consensus reflects epidemiological patterns where H3N2-dominant seasons typically accumulate 80–90 hospitalizations per 100k by early March, driven by school reopenings, waning vaccine efficacy, and baseline transmission dynamics. Supporting evidence includes consistent historical baselines amid stable vaccination coverage around 45%. Challenges could arise from an unusually mild season like 2024–25's low activity persisting due to hybrid immunity, or a surge exceeding 100 from novel strains or low uptake, though models imply low probability.
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
音量
$0終了日
Mar 20, 2026マーケット開始日
Mar 12, 2026, 4:38 PM ETResolver
0x69c47De9D...提案された結果: No
異議申し立てなし
最終結果: No
Traders overwhelmingly price the flu hospitalization rate at 80–90 per 100,000 population for Week 10, 2026—aligning with CDC FluView cumulative rates observed during peak influenza season weeks in recent years, such as 82 in 2023–24 and 88 in 2022–23. This consensus reflects epidemiological patterns where H3N2-dominant seasons typically accumulate 80–90 hospitalizations per 100k by early March, driven by school reopenings, waning vaccine efficacy, and baseline transmission dynamics. Supporting evidence includes consistent historical baselines amid stable vaccination coverage around 45%. Challenges could arise from an unusually mild season like 2024–25's low activity persisting due to hybrid immunity, or a surge exceeding 100 from novel strains or low uptake, though models imply low probability.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問